BioGend Therapeutics Statistics

Total Valuation

TPEX:6733 has a market cap or net worth of TWD 3.86 billion. The enterprise value is 3.31 billion.

Market Cap	3.86B
Enterprise Value	3.31B

Important Dates

The next estimated earnings date is Thursday, August 7, 2025.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

TPEX:6733 has 124.26 million shares outstanding. The number of shares has increased by 0.21% in one year.

Current Share Class	124.26M
Shares Outstanding	124.26M
Shares Change (YoY)	+0.21%
Shares Change (QoQ)	+0.96%
Owned by Insiders (%)	4.11%
Owned by Institutions (%)	2.56%
Float	74.68M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	21.52
PB Ratio	4.76
P/TBV Ratio	5.80
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-23.87
EV / Sales	18.45
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-34.50

Financial Position

The company has a current ratio of 25.12, with a Debt / Equity ratio of 0.01.

Current Ratio	25.12
Quick Ratio	24.39
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	-0.09
Interest Coverage	-734.43

Financial Efficiency

Return on equity (ROE) is -16.02% and return on invested capital (ROIC) is -10.16%.

Return on Equity (ROE)	-16.02%
Return on Assets (ROA)	-9.60%
Return on Invested Capital (ROIC)	-10.16%
Return on Capital Employed (ROCE)	-17.17%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.19
Inventory Turnover	2.67

Taxes

Income Tax	-8.31M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -15.26% in the last 52 weeks. The beta is -0.00, so TPEX:6733's price volatility has been lower than the market average.

Beta (5Y)	-0.00
52-Week Price Change	-15.26%
50-Day Moving Average	28.45
200-Day Moving Average	33.56
Relative Strength Index (RSI)	67.36
Average Volume (20 Days)	100,996

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, TPEX:6733 had revenue of TWD 179.57 million and -138.80 million in losses. Loss per share was -1.13.

Revenue	179.57M
Gross Profit	137.68M
Operating Income	-144.68M
Pretax Income	-149.28M
Net Income	-138.80M
EBITDA	-97.32M
EBIT	-144.68M
Loss Per Share	-1.13

Full Income Statement

Balance Sheet

The company has 585.36 million in cash and 8.52 million in debt, giving a net cash position of 576.83 million or 4.64 per share.

Cash & Cash Equivalents	585.36M
Total Debt	8.52M
Net Cash	576.83M
Net Cash Per Share	4.64
Equity (Book Value)	812.65M
Book Value Per Share	6.33
Working Capital	659.66M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -95.50 million and capital expenditures -560,000, giving a free cash flow of -96.06 million.

Operating Cash Flow	-95.50M
Capital Expenditures	-560,000
Free Cash Flow	-96.06M
FCF Per Share	-0.77

Full Cash Flow Statement

Margins

Gross margin is 76.67%, with operating and profit margins of -80.57% and -77.29%.

Gross Margin	76.67%
Operating Margin	-80.57%
Pretax Margin	-83.14%
Profit Margin	-77.29%
EBITDA Margin	-54.20%
EBIT Margin	-80.57%
FCF Margin	n/a

Dividends & Yields

TPEX:6733 does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.21%
Shareholder Yield	n/a
Earnings Yield	-3.59%
FCF Yield	-2.49%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

TPEX:6733 has an Altman Z-Score of 46.44 and a Piotroski F-Score of 2.

Altman Z-Score	46.44
Piotroski F-Score	2